Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy

References

• Gerrits CJ, Jonge MJ, Schellens JH, Stoter G, Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer. 1997;76(7):952–962. doi:10.1038/bjc.1997.4919328159
   PubMedGoogle Scholar
• Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. Camptothecin and its analogues: a review on their chemotherapeutic potential. Nat Prod Res. 2005;19(4):393–412. doi:10.1080/1478641041233129900515938148
   PubMed Web of Science ®Google Scholar
• Ramesh M, Ahlawat P, Srinivas NR. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed Chromatogr. 2010;24(1):104–123. doi:10.1002/bmc.134519852077
   PubMed Web of Science ®Google Scholar
• Palakurthi S. Challenges in SN38 drug delivery: current success and future directions. Expert Opin Drug Deliv. 2015;12(12):1911–1921. doi:10.1517/17425247.2015.107014226206312
   PubMed Web of Science ®Google Scholar
• Bala V, Rao S, Boyd BJ, Prestidge CA. Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38. J Control Release. 2013;172(1):48–61. doi:10.1016/j.jconrel.2013.07.02223928356
   PubMed Web of Science ®Google Scholar
• Smith NF, Figg WD, Sparreboom A. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006;20(2):163–175. doi:10.1016/j.tiv.2005.06.04516271446
   PubMed Web of Science ®Google Scholar
• Senter PD, Beam KS, Mixan B, Wahl AF. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug Chem. 2001;12(6):1074–1080.11716702
   PubMed Web of Science ®Google Scholar
• Yoshimatsu K, Yokomizo H, Fujimoto T, et al. Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer. Anticancer Res. 2007;27(3B):1657–1661.17595792
   PubMed Web of Science ®Google Scholar
• Oostendorp LJ, Stalmeier PF, Pasker-de Jong PC, Van der Graaf WT, Ottevanger PB. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer. Anticancer Drugs. 2010;21(8):749–758. doi:10.1097/CAD.0b013e32833c57cf20616701
   PubMedGoogle Scholar
• Slatter JG, Su P, Sams JP, Schaaf LJ, Wienkers LC. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. Drug Metab Dispos. 1997;25(10):1157–1164.9321519
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7(8):2182–2194.11489791
   PubMed Web of Science ®Google Scholar
• Charasson V, Haaz MC, Robert J. Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab Dispos. 2002;30(6):731–733. doi:10.1124/dmd.30.6.73112019202
   PubMed Web of Science ®Google Scholar
• Du Y, Zhang W, He R, et al. Dual 7-ethyl-10-hydroxycamptothecin conjugated phospholipid prodrug assembled liposomes with in vitro anticancer effects. Bioorg Med Chem. 2017;25(12):3247–3258. doi:10.1016/j.bmc.2017.04.02528465086
   PubMed Web of Science ®Google Scholar
• Sapra P, Zhao H, Mehlig M, et al. Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11-refractory model. Clin Cancer Res. 2008;14(6):1888–1896. doi:10.1158/1078-0432.CCR-07-445618347192
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang J, Mao W, et al. Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies. J Control Release. 2013;166(2):147–158. doi:10.1016/j.jconrel.2012.12.01923266448
   PubMed Web of Science ®Google Scholar
• Patnaik A, Papadopoulos KP, Tolcher AW, et al. Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;71(6):1499–1506. doi:10.1007/s00280-013-2149-223543270
   PubMed Web of Science ®Google Scholar
• Wang J, Sun X, Mao W, et al. Tumor redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy. Adv Mater. 2013;25(27):3670–3676. doi:10.1002/adma.20130092923740675
   PubMed Web of Science ®Google Scholar
• Wang H, Xie H, Wu J, et al. Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery platforms for enhanced antitumor efficacy. Angew Chem Int Ed Engl. 2014;53(43):11532–11537. doi:10.1002/anie.20140668525196427
   PubMedGoogle Scholar
• Santi DV, Schneider EL, Ashley GW. Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation. J Med Chem. 2014;57(6):2303–2314. doi:10.1021/jm401644v24494988
   PubMed Web of Science ®Google Scholar
• Peng CL, Lai PS, Lin FH, Yueh-Hsiu WS, Shieh MJ. Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles. Biomaterials. 2009;30(21):3614–3625. doi:10.1016/j.biomaterials.2009.03.04819395020
   PubMed Web of Science ®Google Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. doi:10.1186/1556-276X-8-10223432972
   PubMed Web of Science ®Google Scholar
• Liu Y, Li M, Yang F, Gu N. Magnetic drug delivery systems. Sci Chin Mat. 2017;60(6):471–486. doi:10.1007/s40843-017-9049-0
   Google Scholar
• Majumder P, Bhunia S, Chaudhuri A. A lipid-based cell penetrating nano-assembly for RNAi-mediated anti-angiogenic cancer therapy. Chem Commun (Camb). 2018;54(12):1489–1492. doi:10.1039/c7cc08517f29359766
   PubMed Web of Science ®Google Scholar
• Fang YP, Chuang CH, Wu YJ, Lin HC, Lu YC. SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study. Int J Nanomedicine. 2018;13:2789–2802. doi:10.2147/IJN.S15842629785106
   PubMed Web of Science ®Google Scholar
• Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine. 2012;7:49–60. doi:10.2147/IJN.S2676622275822
   PubMed Web of Science ®Google Scholar
• Bala V, Rao S, Li P, Wang S, Prestidge CA. Lipophilic prodrugs of SN38: synthesis and in vitro characterization toward oral chemotherapy. Mol Pharm. 2016;13(1):287–294. doi:10.1021/acs.molpharmaceut.5b0078526623947
   PubMed Web of Science ®Google Scholar
• Fang T, Dong Y, Zhang X, Xie K, Lin L, Wang H. Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors. Int J Pharm. 2016;512(1):39–48. doi:10.1016/j.ijpharm.2016.08.03627544846
   PubMedGoogle Scholar
• Bala V, Rao S, Prestidge CA. Facilitating gastrointestinal solubilisation and enhanced oral absorption of SN38 using a molecularly complexed silica-lipid hybrid delivery system. Eur J Pharm Biopharm. 2016;105:32–39. doi:10.1016/j.ejpb.2016.05.02127245285
   PubMed Web of Science ®Google Scholar
• Wei X, Patil Y, Ohana P, et al. Characterization of pegylated liposomal mitomycin C lipid-based prodrug (Promitil) by high sensitivity differential scanning calorimetry and cryogenic transmission electron microscopy. Mol Pharm. 2017;14(12):4339–4345. doi:10.1021/acs.molpharmaceut.6b0086528045540
   PubMedGoogle Scholar
• Drolle E, Kucerka N, Hoopes MI, et al. Effect of melatonin and cholesterol on the structure of DOPC and DPPC membranes. Biochim Biophys Acta. 2013;1828(9):2247–2254. doi:10.1016/j.bbamem.2013.05.01523714288
   PubMedGoogle Scholar
• Wilkosz N, Rissanen S, Cyza M, et al. Effect of piroxicam on lipid membranes: drug encapsulation and gastric toxicity aspects. Eur J Pharm Sci. 2017;100:116–125. doi:10.1016/j.ejps.2017.01.00728087354
   PubMedGoogle Scholar
• Pazin WM, Olivier DDS, Vilanova N, et al. Interaction of Artepillin C with model membranes. Eur Biophys J. 2017;46(4):383–393. doi:10.1007/s00249-016-1183-527785542
   PubMedGoogle Scholar
• Zhang X, Cao M, Xing J, et al. Identification, characterization, and synthesis of process-related impurities in antiproliferative agent TQ-B3203. J Liq Chromatogr Relat Technol. 2016;39(10):488–496. doi:10.1080/10826076.2016.1196216
   Web of Science ®Google Scholar
• Zhang X, Cao M, Xing J, et al. TQ-B3203, a potent proliferation inhibitor derived from camptothecin. Med Chem Res. 2017;26(12):3395–3406. doi:10.1007/s00044-017-2032-5
   Web of Science ®Google Scholar
• Xing J, Liu D, Zhou G, et al. Liposomally formulated phospholipid-conjugated novel near-infrared fluorescence probe for particle size effect on cellular uptake and biodistribution in vivo. Colloids Surf B Biointerfaces. 2018;161:588–596. doi:10.1016/j.colsurfb.2017.11.03329154213
   PubMedGoogle Scholar
• Li J, Cheng X, Chen Y, et al. Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: an in vivo/in vitro evaluation. Int J Pharm. 2016;512(1):262–272. doi:10.1016/j.ijpharm.2016.08.03727545748
   PubMedGoogle Scholar
• Ma J, Domicevica L, Schnell JR, Biggin PC. Position and orientational preferences of drug-like compounds in lipid membranes: a computational and NMR approach. Phys Chem Chem Phys. 2015;17(30):19766–19776. doi:10.1039/c5cp03218k26153345
   PubMedGoogle Scholar
• Irby D, Du C, Li F. Lipid-drug conjugate for enhancing drug delivery. Mol Pharm. 2017;14(5):1325–1338. doi:10.1021/acs.molpharmaceut.6b0102728080053
   PubMed Web of Science ®Google Scholar